Aceroside VIII is a new natural selective hdac6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells

Hyun Wook Ryu, Dong Hun Lee, Dong Hee Shin, Seung Hyun Kim, So Hee Kwon

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The identification of new isoform-specific histone deacetylase inhibitors is important for revealing the biological functions of individual histone deacetylase and for determining their potential use as therapeutic agents. Among the 11 zinc-dependent histone deacetylases that have been identified in humans, histone deacetylase 6 is a structurally and functionally unique enzyme. Here, we tested the inhibitory activity of diarylheptanoids isolated from Betula platyphylla against histone deacetylase 6. Aceroside VIII selectively inhibited histone deacetylase 6 catalytic activity and the combined treatment of aceroside VIII or (-)-centrolobol with A452, another selective histone deacetylase 6 inhibitor, led to a synergistic increase in levels of acetylated α-tubulin. Aceroside VIII, paltyphyllone, and (-)-centrolobol synergistically enhanced the induction of apoptosis and growth inhibition by A452. Consistent with these results, A452 in combination with aceroside VIII, paltyphyllone, or (-)-centrolobol was more potent than either drug alone for the induction of apoptosis. Together, these findings indicate that aceroside VIII is a specific histone deacetylase 6 inhibitor and points to a mechanism by which natural histone deacetylase 6-selective inhibitors may enhance the efficacy of other histone deacetylase 6 inhibitors in colon cancer cells.

Original languageEnglish
Pages (from-to)222-227
Number of pages6
JournalPlanta Medica
Volume81
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

HT29 Cells
Histone Deacetylase Inhibitors
Histone Deacetylases
Diarylheptanoids
Apoptosis
Betula
Therapeutic Uses
Tubulin
Colonic Neoplasms
aceroside VIII
Zinc
Protein Isoforms
Catalyst activity
Enzymes
Growth
Cells
Pharmaceutical Preparations
1,7-bis(4'-hydroxyphenyl)-3-heptanol

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine
  • Organic Chemistry

Cite this

@article{4467c24d0bce4db8a4f0358434111bdd,
title = "Aceroside VIII is a new natural selective hdac6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells",
abstract = "The identification of new isoform-specific histone deacetylase inhibitors is important for revealing the biological functions of individual histone deacetylase and for determining their potential use as therapeutic agents. Among the 11 zinc-dependent histone deacetylases that have been identified in humans, histone deacetylase 6 is a structurally and functionally unique enzyme. Here, we tested the inhibitory activity of diarylheptanoids isolated from Betula platyphylla against histone deacetylase 6. Aceroside VIII selectively inhibited histone deacetylase 6 catalytic activity and the combined treatment of aceroside VIII or (-)-centrolobol with A452, another selective histone deacetylase 6 inhibitor, led to a synergistic increase in levels of acetylated α-tubulin. Aceroside VIII, paltyphyllone, and (-)-centrolobol synergistically enhanced the induction of apoptosis and growth inhibition by A452. Consistent with these results, A452 in combination with aceroside VIII, paltyphyllone, or (-)-centrolobol was more potent than either drug alone for the induction of apoptosis. Together, these findings indicate that aceroside VIII is a specific histone deacetylase 6 inhibitor and points to a mechanism by which natural histone deacetylase 6-selective inhibitors may enhance the efficacy of other histone deacetylase 6 inhibitors in colon cancer cells.",
author = "Ryu, {Hyun Wook} and Lee, {Dong Hun} and Shin, {Dong Hee} and Kim, {Seung Hyun} and Kwon, {So Hee}",
year = "2015",
month = "1",
day = "1",
doi = "10.1055/s-0034-1396149",
language = "English",
volume = "81",
pages = "222--227",
journal = "Planta Medica",
issn = "0032-0943",
publisher = "Georg Thieme Verlag",
number = "3",

}

Aceroside VIII is a new natural selective hdac6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells. / Ryu, Hyun Wook; Lee, Dong Hun; Shin, Dong Hee; Kim, Seung Hyun; Kwon, So Hee.

In: Planta Medica, Vol. 81, No. 3, 01.01.2015, p. 222-227.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aceroside VIII is a new natural selective hdac6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells

AU - Ryu, Hyun Wook

AU - Lee, Dong Hun

AU - Shin, Dong Hee

AU - Kim, Seung Hyun

AU - Kwon, So Hee

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The identification of new isoform-specific histone deacetylase inhibitors is important for revealing the biological functions of individual histone deacetylase and for determining their potential use as therapeutic agents. Among the 11 zinc-dependent histone deacetylases that have been identified in humans, histone deacetylase 6 is a structurally and functionally unique enzyme. Here, we tested the inhibitory activity of diarylheptanoids isolated from Betula platyphylla against histone deacetylase 6. Aceroside VIII selectively inhibited histone deacetylase 6 catalytic activity and the combined treatment of aceroside VIII or (-)-centrolobol with A452, another selective histone deacetylase 6 inhibitor, led to a synergistic increase in levels of acetylated α-tubulin. Aceroside VIII, paltyphyllone, and (-)-centrolobol synergistically enhanced the induction of apoptosis and growth inhibition by A452. Consistent with these results, A452 in combination with aceroside VIII, paltyphyllone, or (-)-centrolobol was more potent than either drug alone for the induction of apoptosis. Together, these findings indicate that aceroside VIII is a specific histone deacetylase 6 inhibitor and points to a mechanism by which natural histone deacetylase 6-selective inhibitors may enhance the efficacy of other histone deacetylase 6 inhibitors in colon cancer cells.

AB - The identification of new isoform-specific histone deacetylase inhibitors is important for revealing the biological functions of individual histone deacetylase and for determining their potential use as therapeutic agents. Among the 11 zinc-dependent histone deacetylases that have been identified in humans, histone deacetylase 6 is a structurally and functionally unique enzyme. Here, we tested the inhibitory activity of diarylheptanoids isolated from Betula platyphylla against histone deacetylase 6. Aceroside VIII selectively inhibited histone deacetylase 6 catalytic activity and the combined treatment of aceroside VIII or (-)-centrolobol with A452, another selective histone deacetylase 6 inhibitor, led to a synergistic increase in levels of acetylated α-tubulin. Aceroside VIII, paltyphyllone, and (-)-centrolobol synergistically enhanced the induction of apoptosis and growth inhibition by A452. Consistent with these results, A452 in combination with aceroside VIII, paltyphyllone, or (-)-centrolobol was more potent than either drug alone for the induction of apoptosis. Together, these findings indicate that aceroside VIII is a specific histone deacetylase 6 inhibitor and points to a mechanism by which natural histone deacetylase 6-selective inhibitors may enhance the efficacy of other histone deacetylase 6 inhibitors in colon cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84923345812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923345812&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1396149

DO - 10.1055/s-0034-1396149

M3 - Article

C2 - 25590368

AN - SCOPUS:84923345812

VL - 81

SP - 222

EP - 227

JO - Planta Medica

JF - Planta Medica

SN - 0032-0943

IS - 3

ER -